A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Table 4 Toxicities in patients aged more than 60 years who received h-R3/RT or CDDP/RT. (N = 14)

Toxicities (RTOG Grade)	h-R3/RT (N = 7) [n (%)]	CDDP/RT (N = 7) [n (%)]	P Value*
WBC			0.102
(1&2)	3 (42.9%)	5 (71.4%)
(3&4)	0 (0.00%)	0 (0.00%)
PLT			0.059
(1&2)	5 (71.4%)	1 (14.3%)
(3&4)	0 (0.00%)	0 (0.00%)
HB			0.157
(1&2)	2 (28.6%)	5 (71.4%)
(3&4)	0 (0.00%)	0 (0.00%)
ALT			0.317
(1&2)	0 (0.00%)	1 (14.3%)
(3&4)	0 (0.00%)	0 (0.00%)
AST			0.317
(1&2)	0 (0.00%)	1 (14.3%)
(3&4)	0 (0.00%)	0 (0.00%)
GGT			1.000
(1&2)	0 (0.00%)	0 (0.00%)
(3&4)	0 (0.00%)	0 (0.00%)
Dermatitis			0.317
(1&2)	4 (57.1%)	7 (100%)
(3&4)	0 (0.00%)	0 (0.00%)
Rash			1.000
(1&2)	0 (0.00%)	0 (0.00%)
(3&4)	0 (0.00%)	0 (0.00%)
Mucositis			0.891
(1&2)	2 (28.6%)	3 (42.9%)
(3&4)	4 (57.1%)	2 (52.4%)
Taste change			1.000
yes	5 (71.4%)	6 (85.7%)
no	2 (28.6%)	1 (14.3%)
Vomit			0.020
only nausea	0 (0.00%)	1 (2.4%)
Nausea and vomit	0 (0.00%)	5 (71.4%)
Weight loss			0.174
(1&2)	2 (28.6%)	4 (57.1%)
(3&4)	1 (14.3%)	2 (26.2%)

Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
* All p values were obtained by use of the paired rank sum test

ISSN: 1471-2407